2008Australasian biotechnologyRequires access

Tough Times for Biotechs

Tim Boreham

Open publisher page 0 citations

Abstract

The market's aversion to speculative or complex investment propositions which has resulted in only six stocks managing to gain, while 102 declined by more than 10 per cent. A brief note on the companies, their business and the extent of loss or gain is provided.

About this research paper

What this paper is about

The market's aversion to speculative or complex investment propositions which has resulted in only six stocks managing to gain, while 102 declined by more than 10 per cent. A brief note on the companies, their business and the extent of loss or gain is provided.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The market's aversion to speculative or complex investment propositions which has resulted in only six stocks managing to gain, while 102 declined by more than 10 per cent. A brief note on the companies, their business and the extent of loss or gain is provided.

Key concepts: Project commissioning, Investment (military), Publishing, Economics, Business, Management, Political science, Law

Related papers

Back to paper searchBrowse research topicsOriginal source
Tough Times for Biotechs — Research Paper | ScholarLens